Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Pathogens More Abundant in Mouths of Parkinson’s Patients

Opportunistic pathogens — microorganisms that live in us all,  but under specific circumstances can cause diseases like pneumonia — are more abundant in the mouths of people with Parkinson’s disease than healthy individuals, a study reported. This finding suggests that changes in oral bacteria in patients are related to disease…

Study: Alcohol, Tobacco Use May Reduce Parkinson’s Risk

Drinking alcohol and smoking tobacco may reduce a person’s risk of developing Parkinson’s disease, according to a new study that found evidence of a cause-and-effect relationship. “It is crucial to be aware that smoking and drinking pose serious health risks to individuals,” the researchers wrote, noting there was “no…

Parkinson’s Neurons Form Atypical Networks

Parkinson’s disease brain cells form abnormal networks that might predispose the cells toward damage, according to new research done using cells in laboratory conditions. “These discoveries open the door to early diagnosis, which would allow us to carry out a premature intervention that would slow down neuronal death, and…

Voice-assisted Devices May Help Patients to Speak More Clearly

People with Parkinson’s disease who use voice-assisted technologies (VATs) — software programs that respond to voice commands, like Amazon’s Alexa or Apple’s Siri — may find that they help to improve their speech by prodding them to practice speaking more clearly, a study based on an online patient survey…

Stem Cell Therapy Shows Safety, Possible Efficacy in Early Trial

Treatment with ISC-hpNSC, an investigational stem cell therapy for Parkinson’s disease, was safe and well-tolerated over at least two years in an early clinical trial in 12 patients. Results from the small trial, which treated patients at low, medium and high doses, also indicate that the therapy eased Parkinson’s-related symptoms…

Differences in Mouse, Human Astrocytes May Impact Research

Brain cells called astrocytes behave differently under stressful conditions in humans as compared with mice, new research suggests. Because mice are a commonly used model for research in Parkinson’s disease, these “species-specific differences” could have important implications for how such research is done, according to a team of…

Many Who Start Antipsychotics Discontinue Treatment

More than a third of people with Parkinson’s disease who are prescribed antipsychotics stop treatment within six months of starting, a new database analysis suggests. The data also indicate that rates of treatment discontinuation are lower with Nuplazid (pimavanserin) than with other antipsychotics. The findings were published in …

MJFF Offering Online Guide for Patients Considering DBS

The Michael J. Fox Foundation (MJFF) has released a new guide that aims to help people with Parkinson’s disease and their loved ones make informed decisions about deep brain stimulation (DBS), a surgical treatment for the disorder’s motor symptoms. The 22-page guide, which is freely available online,…